Mandate

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

January 14, 2026

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.

The purchase price amounted to USD 91 million. Furthermore, Orexo is entitled to a contingent consideration of up to USD 16.8 million, based on future Zubsolv net sales during 2026 and 2027. Steptoe LLP acted as lead legal counsel in connection with the transaction and Vinge advised Orexo in relation to Swedish law.

Vinge’s team consisted of Rikard Lindahl, Viveka Classon, Kim Bergman Aldevinge and Sara Stålebring.

Related

Vinge has advised Montrose by Carnegie AB on its application for authorisation to conduct securities business

Vinge has successfully advised Montrose by Carnegie AB in connection with its application to the Swedish Financial Supervisory Authority for authorisation to conduct securities business. The authorisation was granted by the Swedish Financial Supervisory Authority on 2 July 2026.
August 12, 2026

Vinge advises Mjällby AIF on the transfer of Elliot Stroud to Hull City AFC

Vinge has advised reigning Allsvenskan champions Mjällby AIF in connection with the transfer of Swedish international Elliot Stroud to Premier League club Hull City AFC.
August 10, 2026

Vinge advises Altor on its public offer for Sleep Cycle

Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026